ImpediMed Limited Net Income

The latest net income for IPD.AX is $-48M as of June 2026. That compares with $-40M in the prior-year period — down 19.4% year over year. That is below the sector sector average of $1.7T. Investors often review this figure alongside ImpediMed Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPD.AX's net income moved from $-40M to $-48M — a 19.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImpediMed Limited's operating scale or balance-sheet position.

Against its sector companies, IPD.AX currently prints $-48M for net income, while the sector average sits near $1.7T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at ImpediMed Limited's growth, margins, and balance sheet.

A net income figure of $-48M for IPD.AX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.7T. Explore the charts below for those layers of context.

After noting IPD.AX's net income ($-48M), review year-over-year change from $-40M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.